文献速递泌尿生殖技术与安全MRUS

显微超声与多参数MRI在前列腺穿刺活检未行男性中检测前列腺癌的比较

Comparison of Micro-US and Multiparametric MRI for Prostate Cancer Detection in Biopsy-Naive Men.
PubMed 文献 · Radiology · 2022-07-19

前瞻性单中心试验纳入94例疑似前列腺癌且未行活检的男性,比较多参数MRI与显微超声靶向活检对临床显著前列腺癌(分级组≥2)的检出率。MRI与显微超声靶向活检检出率分别为39%与35%,差异无统计学意义(P=.22);MRI路径避免活检的比例高于显微超声(34% vs 10%,P<.001)。在MRI与显微超声靶向活检基础上加做非靶向系统活检未增加临床显著前列腺癌检出,但额外检出9例临床不显著前列腺癌(P=.04)。

要点

  • MRI与显微超声靶向活检对临床显著前列腺癌检出率相似(39% vs 35%,P=.22)。
  • MRI路径避免活检比例高于显微超声(34% vs 10%,P<.001)。
  • 93个MRI靶点中62个(67%)在显微超声下可见,可行实时靶向活检。

核心结论

  • MRI与显微超声对前列腺癌检出率相似,但MRI路径避免活检的比例更高;在MRI联合显微超声靶向活检路径中加做非靶向系统活检未额外检出临床显著前列腺癌,仅额外检出临床不显著前列腺癌。

研究设计与样本

  • 前瞻性单中心试验,2019年5月至2020年9月纳入94例疑似前列腺癌且未行活检的男性(中位年龄61岁,IQR 57-68岁),所有患者行多参数MRI后行显微超声,两者结果盲法判读,随后行显微超声引导靶向活检及非靶向系统活检,比例比较采用精确McNemar检验。

诊断标准与关键数值

  • 临床显著前列腺癌定义为分级组≥2。
  • MRI靶向活检检出临床显著前列腺癌37/94(39%),显微超声靶向活检检出33/94(35%),P=.22。
  • MRI靶向活检检出临床不显著前列腺癌14/94(15%),显微超声靶向活检检出15/94(16%),P>.99。
  • MRI靶向活检检出筛状和/或导管内前列腺癌14/94(15%),显微超声靶向活检检出13/94(14%),P>.99。
  • MRI联合显微超声靶向活检路径检出临床显著前列腺癌38/94(40%)。

临床应用与阅片要点

  • MRI与显微超声靶向活检对临床显著前列腺癌检出率相似,MRI路径避免活检的比例更高(34% vs 10%,P<.001)。
  • 在MRI联合显微超声靶向活检路径中加做非靶向系统活检未额外检出临床显著前列腺癌,但额外检出9例临床不显著前列腺癌(P=.04)。
  • 93个MRI靶点中62个(67%)在显微超声下前瞻性可见,支持显微超声实时靶向活检。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Multiparametric MRI has led to increased detection of clinically significant prostate cancer (csPCa). Micro-US is being investigated for csPCa detection. Purpose To compare multiparametric MRI and micro-US in detecting csPCa (grade group ≥2) and to determine the proportion of MRI nodules visible at micro-US for real-time targeted biopsy. Materials and methods This prospective, single-center trial enrolled biopsy-naive men with suspected prostate cancer (PCa) between May 2019 and September 2020. All patients underwent multiparametric MRI followed by micro-US; findings at both were interpreted in a blinded fashion, followed by targeted biopsy and nontargeted systematic biopsy using micro-US. Proportions were compared using the exact McNemar test. The differences in proportions were calculated. Results Ninety-four men (median age, 61 years; IQR, 57-68 years) were included. MRI- and micro-US-targeted biopsy depicted csPCa in 37 (39%) and 33 (35%) of the 94 men, respectively (P = .22); clinically insignificant PCa in 14 (15%) and 15 (16%) (P > .99); and cribriform and/or intraductal PCa in 14 (15%) and 13 (14%) (P > .99). The MRI- plus micro-US-targeted biopsy pathway depicted csPCa in 38 of the 94 (40%) men. The addition of nontargeted systematic biopsy to MRI- plus micro-US-targeted biopsy did not enable identification of any additional men with csPCa but did help identify nine additional men with clinically insignificant PCa (P = .04). Biopsy was avoided in 32 of the 94 men (34%) with MRI and nine of the 94 men (10%) with micro-US (P < .001). Among 93 MRI targets, 62 (67%) were prospectively visible at micro-US. Conclusion MRI and micro-US showed similar rates of prostate cancer detection, but more biopsies were avoided with the MRI pathway than with micro-US, with no benefit of adding nontargeted systematic biopsy to the MRI- plus micro-US-targeted biopsy pathway. Most MRI lesions were prospectively visible at micro-US, allowing real-time targeted biopsy. ClinicalTrials.gov registration no.: NCT03938376 © RSNA, 2022 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ghai, Perlis, Atallah, et al. Comparison of Micro-US and Multiparametric MRI for Prostate Cancer Detection in Biopsy-Naive Men. Radiology. 2022. PMID: 35852425. doi:10.1148/radiol.212163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。